Drugs / Autologous Adipose MSC's
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04352803 | Apr 2020 → Apr 2024 | cytokine release syndrome, pneumonia | Regeneris Medical | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Adipose MSC's | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04352803 ↗ |
| Known as | Autologous Adipose Derived Mesenchymal Cells | “Autologous Adipose Derived Mesenchymal Cells 500,000/kg IV” NCT04352803 ↗ |
| Modality | Cell therapy | “Mesenchymal cells are a potential privileged cell-based therapy in SARS-CoV-2.” NCT04352803 ↗ |
| Route | Intravenous | “autologous adipose-derived mesenchymal cells given IV to eligible patients” NCT04352803 ↗ |